Announcements Trials
Browse Landscape

Phase

Phase 2 6

Status

Active not recruiting 11Recruiting 6Unknown 5Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2OTHER_GOV 1

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 4Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Non-Small Cell Lung Cancer Metastatic 1Lazertinib 1Advanced Solid Tumors 1

Interventions

pembrolizumab 555Specimen Handling 459Carboplatin 446Magnetic Resonance Spectroscopy 427Cyclophosphamide 412Cisplatin 404Gemcitabine 314Radiotherapy 313Bevacizumab 310Paclitaxel 300Biopsy 260Drug Therapy 252Capecitabine 241Oxaliplatin 240fludarabine 236Nivolumab 226venetoclax 225Injections 214Docetaxel 203Fluorouracil 201Dexamethasone 186Radiosurgery 172Rituximab 161Pemetrexed 157durvalumab 144Standard of Care 143atezolizumab 139toripalimab 137tislelizumab 137Leucovorin 137

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Interventional × lazertinib × Clear all
NCT05498428 2026-05-08

PALOMA-2

Janssen Research & Development, LLC

Phase 2 Recruiting
520 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06667076 2026-05-08

COPERNICUS

Janssen Research & Development, LLC

Phase 2 Recruiting
480 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06106802 2026-02-23

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

Samsung Medical Center

Phase 2 Recruiting
47 enrolled
Thoracic

Non-Small Cell Lung Cancer Metastatic

NCT06268210 2026-02-09

NeoLazer

Yonsei University

Phase 2 Recruiting
160 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05541822 2025-05-22

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Abion Inc

Phase 2 Recruiting
178 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT06156527 2023-12-05

A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

National Cancer Center, Korea

Phase 2 Recruiting
120 enrolled

Lazertinib

Data powered by HemOnc (CC BY 4.0) Colophon âš¡